The respiratory syncytial virus causes substantial morbidity and mortality, and although the palivizumab prophylaxis treatment is effective for high-risk infants, there is a need to develop a vaccine for general use. In this trial, the authors evaluated the candidate vaccine LID∆M2-2. The results showed an excellent infectivity and immunogenicity, supporting further study of similar candidate vaccines.
Live-attenuated respiratory syncytial virus vaccine candidate with deletion of RNA synthesis regulatory protein M2-2 is highly immunogenic in children
Written By
McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2000 study team
